EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Ligelizumab in adolescents with chronic spontaneous urticaria: Results of a dedicated phase 2b randomized clinical trial supported with pharmacometric analysis

Petra Staubach, Montserrat Alvaro-Lozano iD, Bulent Enis Sekerel iD, Marcus Maurer iD, Moshe Ben-Shoshan, Miriam Porter, Eva Hua, Yan Ji, Alis Burciu, Marina Savelieva, Thomas Severin, Anton Drollmann und 1 weitere

Pediatric Allergy and Immunology · 2023

DOI: 10.1111/pai.13982 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Pediatric Allergy and Immunology, 2023. Verfasst von Petra Staubach und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Medical Center, Mainz, Germany. Hauptthemen laut MEDLINE: Anti-Allergic Agents, Urticaria, Chronic Urticaria. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic spontaneous urticaria (CSU), a long‐lasting disease in children, impacts their quality of life. We report the results of a phase 2b dose‐finding trial of ligelizumab ( NCT03437278 ) and a high‐affinity humanized monoclonal anti‐IgE antibody, in adolescents with CSU, supported by modeling and simulation analyses, mitigating challenges in pediatric drug development.

Methods

This multicenter, double‐blind, placebo‐controlled trial, randomized H1‐antihistamine‐refractory adolescent CSU patients (12–18 years) 2:1:1 to ligelizumab 24 mg, 120 mg, or placebo every 4 weeks for 24 weeks. Patients on placebo transitioned to ligelizumab 120 mg at week 12. Integrating data from the previous adult and present adolescent trial of ligelizumab, a nonlinear mixed‐effects modeling described the longitudinal changes in ligelizumab pharmacokinetics, and its effect on weekly Urticaria Activity Score (UAS7).

Results

Baseline UAS7 (mean ± SD) was 30.5 ± 7.3 ( n = 24), 29.3 ± 7.7 ( n = 13), and 32.5 ± 9.0 ( n = 12) for patients (median age, 15 years) on ligelizumab 24 mg, 120 mg, and placebo, respectively. Change from baseline in UAS7 at week 12 with ligelizumab 24 mg, 120 mg, and placebo was −15.7 ± 10.9, −18.4 ± 12.3, and −13.0 ± 13.0, respectively. Ligelizumab was well‐tolerated. The modeling analysis showed that body weight, but not age, affected ligelizumab's apparent clearance. No significant differences between adolescents and adults were detected on the model‐estimated maximum effect and potency.

Conclusions

Ligelizumab exhibited efficacy and safety in adolescent CSU patients, consistent with that in adults. The PK and potency of ligelizumab were not impacted by age, and the same dose of ligelizumab can be used for treating adolescents and adults with CSU. Our study shows how modeling and simulation can complement pediatric drug development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Allergic AgentsUrticariaChronic UrticariaAdultHumansAdolescentChildOmalizumabQuality of LifeTreatment OutcomeChronic DiseaseAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

adolescentanti-IgEchronic spontaneous urticariaexposure-responseligelizumabmodelingpediatricpharmacodynamicpharmacokineticsimulation

Substanzen

Anti-Allergic AgentsOmalizumabligelizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Dermatology, University Medical Center, Mainz, Germany.
  • Department of Pediatric Allergology and Clinical Immunology, Hospital Sant Joan de Déu, Esplugues (Barcelona), Institut de Recerca Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain.
  • Faculty of Medicine, Pediatric Allergy and Asthma Unit, Hacettepe University, Ankara, Turkey.
  • Institute of Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.
  • Division of Allergy and Clinical Immunology, Department of Paediatrics, Montreal Children's Hospital McGill University Health Centre, Montreal, Quebec, Canada.

ORCID-Profile: Montserrat Alvaro-Lozano, Bulent Enis Sekerel, Marcus Maurer

Zitieren

APA

Staubach, P., Alvaro-Lozano, M., Sekerel, B. E., Maurer, M., Ben-Shoshan, M., Porter, M., Hua, E., Ji, Y., Burciu, A., Savelieva, M., Severin, T., Drollmann, A., & Bienczak, A. (2023). Ligelizumab in adolescents with chronic spontaneous urticaria: Results of a dedicated phase 2b randomized clinical trial supported with pharmacometric analysis. Pediatric Allergy and Immunology. https://doi.org/10.1111/pai.13982

Vancouver

Staubach P, Alvaro-Lozano M, Sekerel BE, Maurer M, Ben-Shoshan M, Porter M, et al. Ligelizumab in adolescents with chronic spontaneous urticaria: Results of a dedicated phase 2b randomized clinical trial supported with pharmacometric analysis. Pediatric Allergy and Immunology. 2023. doi:10.1111/pai.13982

BibTeX
@article{Staubach2023,
  author = {Staubach, Petra and Alvaro-Lozano, Montserrat and Sekerel, Bulent Enis and Maurer, Marcus and Ben-Shoshan, Moshe and Porter, Miriam and Hua, Eva and Ji, Yan and Burciu, Alis and Savelieva, Marina and Severin, Thomas and Drollmann, Anton and Bienczak, Andrzej},
  title = {Ligelizumab in adolescents with chronic spontaneous urticaria: Results of a dedicated phase 2b randomized clinical trial supported with pharmacometric analysis},
  journal = {Pediatric Allergy and Immunology},
  year = {2023},
  doi = {10.1111/pai.13982}
}
Kostenlos starten →